Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Given their glucose-lowering effects, GLP-1s have become standard of care for type 2 diabetes, supplanting other medication classes such as sulfonylureas.2 In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.2 While diabetes GLP-1s will continue to account for a greater portion of spend compared to obesity, costs related to GLP-1s prescribed for obesity are expected to grow at a faster rate over the next 3 years
Treatment for this specific condition should not be taken lightly as it can quickly become life-threatening if not treated properly
Agric Food Chem
The increasing rates of obesity and diabetes in the U.S
Studies were conducted with these compounds, which created the way to this pairing
Medication Claims and Limitations We assess how clearly clinics explain the limits of their treatments
